CN1582279A - 过氧化物酶体激活的受体激动剂 - Google Patents

过氧化物酶体激活的受体激动剂 Download PDF

Info

Publication number
CN1582279A
CN1582279A CNA028238001A CN02823800A CN1582279A CN 1582279 A CN1582279 A CN 1582279A CN A028238001 A CNA028238001 A CN A028238001A CN 02823800 A CN02823800 A CN 02823800A CN 1582279 A CN1582279 A CN 1582279A
Authority
CN
China
Prior art keywords
methyl
oxo
propionic acid
benzyl
phenoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028238001A
Other languages
English (en)
Chinese (zh)
Inventor
T·A·吉布森
R·D·约翰斯顿
N·B·曼特洛
R·C·汤普森
王晓东
L·L·小温纳罗斯基
徐彦平
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN1582279A publication Critical patent/CN1582279A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CNA028238001A 2001-11-30 2002-11-26 过氧化物酶体激活的受体激动剂 Pending CN1582279A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33445301P 2001-11-30 2001-11-30
US60/334,453 2001-11-30

Publications (1)

Publication Number Publication Date
CN1582279A true CN1582279A (zh) 2005-02-16

Family

ID=23307275

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028238001A Pending CN1582279A (zh) 2001-11-30 2002-11-26 过氧化物酶体激活的受体激动剂

Country Status (19)

Country Link
US (1) US7544812B2 (enExample)
EP (1) EP1453811A2 (enExample)
JP (1) JP2005517643A (enExample)
KR (1) KR20050044606A (enExample)
CN (1) CN1582279A (enExample)
AU (1) AU2002356927A1 (enExample)
BR (1) BR0214437A (enExample)
CA (1) CA2468846A1 (enExample)
CO (1) CO5640129A2 (enExample)
EA (1) EA007163B1 (enExample)
HR (1) HRP20040469A2 (enExample)
HU (1) HUP0402486A3 (enExample)
IL (1) IL161578A0 (enExample)
MX (1) MXPA04005123A (enExample)
NO (1) NO20042737L (enExample)
NZ (1) NZ532909A (enExample)
PL (1) PL370515A1 (enExample)
WO (1) WO2003048130A2 (enExample)
ZA (1) ZA200404173B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101875636A (zh) * 2010-05-18 2010-11-03 浙江大学 咪唑啉-2,4-二酮类衍生物及制备方法和用途
CN115894379A (zh) * 2022-01-20 2023-04-04 中国药科大学 海因类化合物及其医药用途

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0311834A (pt) 2002-06-19 2005-04-12 Lilly Co Eli Composto, composição farmacêutica, métodos para mudular um receptor ativado por proliferador de peroxisoma, para tratar e prevenir diabetes mellitus em um mamìfero e para tratar sìndrome x em um mamìfero, e, uso de um composto ou seu sal farmaceuticamente aceitável
US7816385B2 (en) * 2002-12-20 2010-10-19 High Point Pharmaceuticals, Llc Dimeric dicarboxylic acid derivatives, their preparation and use
DE10351859A1 (de) * 2003-11-06 2005-06-09 Beiersdorf Ag Emulsionen mit zwei Verdickungsmitteln
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
NZ553566A (en) * 2004-09-28 2010-11-26 Allergan Inc Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same
BRPI0713320A2 (pt) 2006-06-20 2012-02-07 Wyeth Corp inibidores de canal de potássio imidazola kvl.5
FR2903984B1 (fr) * 2006-07-24 2008-10-03 Genfit Sa Derives d'imidazolones substitues, preparation et utilisations
WO2008094860A2 (en) 2007-01-30 2008-08-07 Allergan, Inc. Treating ocular diseases using peroxisome proliferator-activated receptor delta antagonists
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
DK2170930T3 (da) 2007-06-04 2012-11-05 Synergy Pharmaceuticals Inc Agonister af guanylatcyclase, anvendelige til behandlingen af gastrointestinale sygdomme, inflammation, cancer og andre sygdomme
EP2328910B1 (en) 2008-06-04 2014-08-06 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法
CN114835655A (zh) * 2022-04-14 2022-08-02 河南师范大学 一种合成光学活性三氟甲基丙烯酸酯类化合物的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3452041A (en) * 1965-05-19 1969-06-24 American Home Prod Hydantoin compounds and methods of preparation
CA1176261A (en) 1976-06-03 1984-10-16 Albert G. Caldwell Hydantoin derivatives
GB1601310A (en) 1978-05-23 1981-10-28 Lilly Industries Ltd Aryl hydantoins
JPS59159163A (ja) * 1983-03-01 1984-09-08 Fuji Photo Film Co Ltd ハロゲン化銀カラ−感光材料
GB9604242D0 (en) 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
WO1998039303A1 (en) * 1997-03-03 1998-09-11 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
AU7073400A (en) 1999-08-27 2001-03-26 Eli Lilly And Company Biaryl-oxa(thia)zole derivatives and their use as ppars modulators

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101875636A (zh) * 2010-05-18 2010-11-03 浙江大学 咪唑啉-2,4-二酮类衍生物及制备方法和用途
CN115894379A (zh) * 2022-01-20 2023-04-04 中国药科大学 海因类化合物及其医药用途

Also Published As

Publication number Publication date
NO20042737L (no) 2004-08-17
PL370515A1 (en) 2005-05-30
US7544812B2 (en) 2009-06-09
WO2003048130A2 (en) 2003-06-12
HUP0402486A3 (en) 2007-05-02
CO5640129A2 (es) 2006-05-31
HRP20040469A2 (en) 2004-10-31
AU2002356927A1 (en) 2003-06-17
KR20050044606A (ko) 2005-05-12
CA2468846A1 (en) 2003-06-12
EA200400748A1 (ru) 2004-12-30
JP2005517643A (ja) 2005-06-16
BR0214437A (pt) 2004-10-13
EA007163B1 (ru) 2006-08-25
WO2003048130A3 (en) 2003-11-20
US20050020652A1 (en) 2005-01-27
MXPA04005123A (es) 2005-02-17
HUP0402486A2 (hu) 2005-03-29
EP1453811A2 (en) 2004-09-08
IL161578A0 (en) 2004-09-27
ZA200404173B (en) 2005-08-23
NZ532909A (en) 2006-08-31

Similar Documents

Publication Publication Date Title
CN1582279A (zh) 过氧化物酶体激活的受体激动剂
CN1479728A (zh) 过氧化物酶体增殖子激活受体α激动剂
CN1289469C (zh) α－(N－磺酰氨基)乙酰胺衍生物作为β－淀粉样蛋白抑制剂
CN1157368C (zh) 人过氧化物酶体增殖剂活化受体(PPAR)α激动剂-取代苯基丙酸衍生物
CN1048159C (zh) 制备含咪唑基链烯酸的药物组合物的方法
CN1277824C (zh) 哌嗪衍生物
CN1230431C (zh) 用作类胰蛋白酶抑制剂的芳基甲胺衍生物
CN1158254C (zh) 作为基质金属蛋白酶抑制剂的β-磺酰基异羟肟酸
CN1909902A (zh) 用于治疗糖尿病的作为ppar调节剂的三唑、噁二唑和噻二唑衍生物
CN1714079A (zh) 扁桃酸衍生物
CN1558897A (zh) 口服抗糖尿病剂
CN1751037A (zh) 作为ppar调节剂的磺酰胺衍生物
CN1111622A (zh) 丙烯酸衍生物
CN1662230A (zh) 作为PPARα和γ调节剂的苯甲酸衍生物
CN1035817C (zh) 三唑基取代的叔胺化合物及其盐的制备方法
CN1263758C (zh) 3，7－二氮杂双环[3.3.0]辛烷及其在治疗心脏心律失常中的用途
CN1662487A (zh) 酰胺连接基过氧化物酶体增殖物激活受体调节剂
CN1906154A (zh) 氨基醇衍生物
CN1227248C (zh) 咪唑烷衍生物、它们的制备方法以及它们用于制备抗炎药的用途
CN1047860A (zh) 丁烯酸衍生物
CN1894235A (zh) 用作由因子Ⅶa诱导的凝血因子Xa、IXa和凝血酶形成的抑制剂的N－(4－脒基苄基)－2－烷氧基－2－杂环基乙酰胺
CN1942448A (zh) 新型咪唑
HK1047104A1 (en) Spiroimidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them
CN1649834A (zh) 新的丙酸衍生物
HK1077806B (en) Novel propionic acid derivative

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication